Bmi-1 inhibitor (IC50
~ 0.5 μ
M); irreversibly impairs colorectal cancer-initiating cell (CIC) growth. Reduces tumor growth in CIC xenograft assays and results in reduced potential of colorectal cancer cells to initiate tumors in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Self-renewal as a therapeutic target in human colorectal cancer.
Kreso et al.